This effect is associated with the modulation of gut microbiota, a reduction in inflammatory cytokine levels, and the production of anti-inflammatory metabolites such as IAA and ILA, which collectively contribute to the downregulation of IL-17 signaling and the alleviation of DSS-induced colitis (Figure 6). This evidence concerns the gene IL17A and colitis.